ArticleCancers2023
The Role of Surgery in Primary Chest Wall Tumors: Over 20 Years' Experience in Resection and Reconstruction.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Evaluation of the Effectiveness and Safety of the Use of CODUBIXJournal of clinical medicine · 2026Article
- Impact of Surgical Margins in Chest Wall Chondrosarcomas: A CanSaRCC Study.Journal of surgical oncology · 2026Observational
- The evaluation of cognitive workload associated with indocyanine green fluorescence angiography in colorectal surgery.Surgical endoscopy · 2026Article
- Chest Wall Resection and Reconstruction Following Cancer.Current oncology (Toronto, Ont.) · 2025Review
- Robotic-assisted costectomy using a Gigli saw for fibrous dysplasia.Journal of cardiothoracic surgery · 2025Article
- Chest wall resections for sulcus superior tumors.Journal of thoracic disease · 2024Review
- Biochemical implications of robotic surgery: a new frontier in the operating room.Journal of robotic surgery · 2024Review
- Comparing Pediatric and Adult Primary Chest Wall Tumors.Journal of clinical practice and research · 2023Article
- Robotic chest wall resection for primary benign chest wall tumors and locally advanced lung cancer: an institutional case series and national report.Journal of thoracic disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary chest wall tumors comprise a heterogeneous group of neoplasms arising from soft tissues and bones. While surgical excision is the standard of care for benign tumors, the management of malignant tumors requires multimodal treatment. We conducted a predictive analysis of outcome, recurrence-free and overall survival.
methodsWe retrospectively reviewed the clinical and pathological records of all patients treated in our center between 1998 and 2020.
results53 patients (15-85 years) were treated in our department. The average tumor diameter was 65 ± 35 mm (10-160 mm). Negative margins were obtained in 48 patients (90.6%), whereas in the remaining 5, R1 resection was accomplished. Median overall survival was 63,03 months (1-282 months). Overall survival was 90% at 1 year, 78% at 2 years, and 61% at 5 years. Our analysis identified tumor diameter, postoperative complications, and high grade of malignancy as factors that can influence prognosis.
conclusionsThe treatment of primary chest wall tumors remains a very challenging process. Different histological types preclude definition of an unequivocal approach. Complete resection with healthy margins remains a definitive cornerstone in the treatment of these cancers as part of a more comprehensive approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.